Therefore, the present trial was designed to evaluate the safety and immunological efficacy of low-dose reirradiation in combination with polyinosinic:polycytidylic acid (poly I:C) and granulocyte-macrophage colony stimulating factor (GM-CSF) in adult patients with recurrent WHO grade IV glioma. This evidence concerns the gene CSF2 and central nervous system cancer.